Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine

Neurology

Volumn 50, Issue 5 SUPPL. 5, 1998, Pages

  Chase, Thomas N ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING); BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; DEXTROMETHORPHAN; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DYNORPHIN; ENKEPHALIN; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTENSIN; OXIDOPAMINE; PRAMIPEXOLE; RECEPTOR SUBTYPE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SUBSTANCE P; TOLCAPONE; UNINDEXED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0031954732     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.5_suppl_5.s17     Document Type: Article

References (69)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
3. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17(suppl 2): S32-44.
4. Bunney B, Walters JR, Roth RH, Aghajaxian GK. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 1973;185:560-571.
5. Schultz W. Behavior-related activity of primate dopamine neurons. Rev Neurol (Paris) 1994;150:634-639.
6. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(suppl 6): S15-18.
7. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1988;25:523-526.
8. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in Parkinsonism. Ann Neurol 1980;8:558-563.
9. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
10. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24: 366-371.
11. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24: 372-378.
12. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor-response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
13. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
14. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
15. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48: 369-372.
16. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in Parkinson's disease. Neurology 1975;25:1144-1148.
17. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nature [New Biol] 1973;245:150-151.
18. Hornykiewicz O. Brain monoamines and parkinsonism. In: Bernard BK, ed. Aminergic hypothesis of behavior: reality or cliché? Rockville, MD: National Institute on Drug Abuse, 1975:13-21.
19. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
20. Schwarting RKW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996;50:275-331.
21. Marin C, Papa SM, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996;736:202-205.
22. Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett 1997;228:5-8.
23. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989;168: 291-298.
24. Bédard PJ, Mancilla BG, Blanchett P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
25. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
26. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
27. Guttman M. Dopamine receptors in Parkinson's disease. Neurol Clin 1992; 10:377-386.
28. 2 agonists on rotational behavior and dopamine receptor binding. Eur J Pharmacol 1993;236: 385-393.
29. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118.
30. 2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 1992;581:261-268.
31. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
32. 2 agonists. Eur J Pharmacol 1991;200: 171-173.
33. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44: 163-196.
34. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995; 701:13-18.
35. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578.
36. Blanchet PJ, Verhagen Metman L, Mouradian M, Chase TN. Acute pharmacological blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
37. Verhagen Metman L, Blanchet PJ, Mouradian MM, Chase TN. Dextromethorphan and levodopa combination therapy in Parkinson's patients with response fluctuations [Abstract]. Mov Disord 1996;11:184.
38. Huang CC, Gean PW. Cyclic adenosine-3′,5′-monophosphate potentiates the synaptic potential mediated by NMDA receptors in the amygdala. J Neurosci Res 1995;40:747-754.
39. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
40. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781.
41. Goetz CG, Tanner CM, Klawans HL, Shannon KM, Carroll VS. Parkinson's disease and motor fluctuations: long-acting carbidopda/levodopa (CR-4-Sinemet). Neurology 1987;37:875-878.
42. Hutton JT, Morris JL. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. Neurology 1992;42(suppl 1):51-56.
43. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(suppl 2):S25-32.
44. Lees AJ. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease. Adv Neurol 1990;53: 475-482.
45. 2 receptors. Nature 1980;286:157-159.
46. Seeman P. Brain dopamine receptors. Pharmacol Rev 1981; 32:229-313.
47. 2 agonist effects. Science 1987;236:719-722.
48. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
49. 2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 1993;265:1387-1391.
50. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-12.
51. 4 receptors. Eur J Pharmacol 1995;290:29-36.
52. Parkinson Study Group, Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 1997;278:125-130.
53. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
54. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
55. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
56. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-212.
57. Rinne UK, Bracco F, Chouza C, et al., and the PKDS009 Collaborative Study Group. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
58. 2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9:147-154.
59. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-2688.
60. Goldstein M, Lieberman A. The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology 1992;42(suppl 4):8-12.
61. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.
62. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995;18: 333-337.
63. Kurth MC, Adler CH, Saint-Hilaire M. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
64. Poewe W, Gerstenbrand F, Ransmayr G. Experience with selegiline in the treatment of Parkinson's disease. J Neural Transm Suppl 1987;25:131-135.
65. Sivertsen B, Dupont E, Mikkelsen B, et al. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand 1989;126:147-152.
66. Birkmayer W, Riederer P, Youdin MBH, Linauer W. The potentiation of the anti akinetic effect of L-dopa treatment by an inhibitor of MAO-B, deprenil. J Neural Transm 1975;36:303-326.
67. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
68. Lees AJ, for the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311:1602-1607.
69. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.